文献速递贫血与红细胞疾病

心力衰竭合并贫血的治疗策略

How I treat anemia in heart failure.
PubMed 文献 · Blood · 2020-01-01

贫血影响约30%稳定门诊心衰患者和50%急性失代偿心衰患者,绝对或功能性缺铁见于约50%心衰患者,二者常共存且独立增加死亡和住院风险。促红细胞生成素刺激剂(ESA)改善主观指标但大型试验显示达依泊汀α未改善长期结局且伴不良反应,静脉铁剂研究显示一定获益。本文通过5个常见临床场景介绍基于客观证据的个性化治疗,并提供治疗算法。

要点

  • 贫血和缺铁在心衰患者中高发,独立增加死亡和住院风险。
  • ESA未改善心衰长期结局且伴不良反应,不推荐常规使用。
  • 静脉铁剂可改善心衰主观和一些客观指标,但需更多研究。

核心结论

  • 贫血和缺铁是心衰常见共病,独立增加死亡和住院风险。
  • ESA达依泊汀α未改善射血分数降低心衰患者的长期结局,且与不良反应相关。
  • 静脉铁剂在改善心衰主观和一些客观指标方面取得一定成功,但需更多研究确定最佳治疗。

研究设计与样本

  • 本文为综述,基于现有证据介绍心衰合并贫血的个性化治疗。
  • 文中描述了5个常见心衰合并贫血的临床场景及作者的个人处理方法。
  • 文中提供了一个针对此类患者个性化治疗的指导算法。

主要发现

  • 贫血影响约30%稳定门诊心衰患者和50%急性失代偿心衰患者。
  • 绝对或功能性缺铁见于约50%心衰患者。
  • 小规模研究显示ESA改善心衰主观指标。
  • 大型关键结局试验显示达依泊汀α未改善射血分数降低心衰患者的长期结局,且与不良反应相关。
  • 静脉铁剂研究显示改善心衰主观和一些客观指标。

临床怎么用

  • 基于客观证据,在5个常见临床场景中考虑个性化治疗贫血和缺铁。
  • 参考文中提供的算法指导心衰合并贫血患者的个性化治疗。

局限性

  • 需要更多研究来确定这些高危患者的最佳治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia is a very common comorbidity in patients with heart failure (HF), affecting ∼30% of stable ambulatory patients and 50% patients with acute decompensated HF. Absolute or functional iron deficiency (ID) is seen in ∼50% patients with HF. Both of these comorbidities often coexist and are independently associated with increased mortality and hospitalizations. These findings led several investigators to test the hypotheses that treatment of anemia and ID in HF would improve symptoms and long-term outcomes. Small studies showed that erythropoiesis-stimulating agents (ESAs) improve subjective measures of HF. However, a large pivotal outcome trial found that the ESA darbepoetin alfa did not improve long-term outcomes in patients with HF with reduced ejection fraction and instead was associated with adverse effects. Studies using IV iron have had somewhat greater success, showing improvements in subjective and some objective measures of HF. However, more research is needed to establish the best treatment options for these high-risk patients. We present 5 common scenarios of patients with HF and anemia and describe our personal approach on how we might treat them based on objective evidence where available. An algorithm that offers guidance in regard to personalized therapy for such patients is also presented.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Anand I, Gupta P. How I treat anemia in heart failure. Blood. 2020. PMID: 31895946. doi:10.1182/blood.2019004004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。